Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 290
Filter
1.
Int Nurs Rev ; 60(2): 196-200, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23692002

ABSTRACT

BACKGROUND: A severe earthquake occurred in Japan on 11 March 2011. The giant tsunami devastated many coastal communities in eastern Japan and caused the Fukushima Dai-ichi nuclear power plant incident. The Japanese government conducted a large-scale survey of residents affected by the nuclear and natural disasters in Fukushima prefecture and in response to the government's request, H University dispatched a Radiation Exposure Research Team to Fukushima. PURPOSE: This article explains the activities of the Radiation Exposure Research Team and the role of nurses in a nuclear disaster. CONCLUSION: As a nurse in the field of radiation medicine, our role is to protect the health of those affected and to reduce their anxiety. In addition, as the persons responsible for implementing these projects, it is also necessary that we educate and foster the development of medical care personnel with the appropriate knowledge and skills to carry out the measures required.


Subject(s)
Disasters , Earthquakes , Fukushima Nuclear Accident , Nuclear Power Plants , Nurse's Role , Radiation Injuries/nursing , Tsunamis , Emergency Nursing/organization & administration , Humans , Japan , Radioactive Hazard Release
2.
Diabet Med ; 24(2): 154-60, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17257277

ABSTRACT

AIMS: Type 2 diabetes is preceded by a symptom-free period of impaired glucose tolerance (IGT). Pancreatic B-cell function decreases as glucose intolerance develops. In many patients with IGT, fasting blood glucose is within normal limits and hyperglycaemia occurs only postprandially. We examined whether pancreatic B-cell function changes during acute hyperglycaemia induced by oral glucose loading. METHODS: We calculated the insulinogenic index (I.I.) as an indicator of pancreatic B-cell function and measured serum levels of thioredoxin, a marker of cellular redox state, and 8-hydroxy-2'-deoxyguanosine (8-OHdG), a marker of oxidative stress, during a 75-g oral glucose tolerance test (OGTT) in 45 subjects [24 patients with normal glucose tolerance (NGT), 14 with IGT and seven with Type 2 diabetes]. RESULTS: Thioredoxin levels decreased after glucose loading [66.1 +/- 23.7, *59.3 +/- 22.4, *49.3 +/- 21.2 and *37.7 +/- 18.0 ng/ml, fasting (0 min) and at 30, 60 and 120 min, respectively; *P < 0.001 vs. fasting]. In contrast, concentrations of 8-OHdG peaked at 30 min and then gradually decreased (0.402 +/- 0.123, *0.440 +/- 0.120, 0.362 +/- 0.119 and 0.355 +/- 0.131 ng/ml, *P < 0.05 vs. fasting, P < 0.01 vs. 30 min). The insulinogenic index correlated with the change in thioredoxin levels (r = 0.34, P < 0.05). However, there was no relationship with the change in 8-OHdG levels from 0 to 30 min. CONCLUSIONS: Hyperglycaemia in response to oral glucose impairs pancreatic B-cell function with decreasing thioredoxin levels. The augmented oxidative stress induced by hyperglycaemia may affect the cellular redox state. These findings strongly suggest that repeated postprandial hyperglycaemia may play an important role in the development and progression of diabetes mellitus.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Glucose/pharmacology , Hyperglycemia/complications , Hypoglycemic Agents/pharmacology , Insulin-Secreting Cells/drug effects , Oxidative Stress/drug effects , Administration, Oral , Aged , Female , Glucose/administration & dosage , Glucose Tolerance Test , Humans , Hypoglycemic Agents/administration & dosage , Male , Middle Aged , Thioredoxins/metabolism
4.
Clin Exp Med ; 4(4): 170-3, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15750763

ABSTRACT

Cilostazol is a selective inhibitor of phosphodiesterase III with anti-platelet-aggregatory and vasodilating properties. Randomised, double-blind, placebo-controlled trials in 2702 patients with intermittent claudication demonstrated that cilostazol significantly increased walking distances compared with placebo. Furthermore, the agent has beneficial effects on the serum lipid profile and fatty acid composition in plasma. Consequently, cilostazol may be useful to prevent atherosclerosis from progressing by ameliorating lipid and fatty acid metabolism.


Subject(s)
Atherosclerosis/drug therapy , Fatty Acids/metabolism , Intermittent Claudication/drug therapy , Lipid Metabolism/drug effects , Phosphodiesterase Inhibitors/pharmacology , Tetrazoles/pharmacology , Aged , Cilostazol , Double-Blind Method , Female , Humans , Male , Phosphodiesterase Inhibitors/therapeutic use , Tetrazoles/therapeutic use , Treatment Outcome
5.
Clin Exp Med ; 2(4): 180-4, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12624709

ABSTRACT

Cilostazol is an anti-thrombotic and vasodilating agent, reported to have both anti-thrombotic and cerebral vasodilating effects. We investigated the effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. The serum concentrations of total cholesterol, triglycerides, high-density lipoprotein-cholesterol, lipoprotein (a), remnant-like particles-cholesterol, apolipoproteins, and plasma fatty acid composition were measured in 17 diabetic patients with peripheral vascular disease before and 1, 3, and 6 months after administration of cilostazol (200 mg/day). Serum triglyceride concentrations were significantly decreased after cilostazol (from 1.31+/-0.17 mmol/l to 0.86+/-0.07 mmol/l at 6 months, P<0.01). Plasma docosahexaenoic acid levels were significantly increased after cilostazol (4.11+/-0.26% to 4.94+/-0.26% at 6 months, P<0.01). Our findings show that cilostazol can induce some beneficial changes in serum lipid profile and plasma fatty acid composition.


Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/pathology , Fatty Acids/blood , Lipids/blood , Peripheral Vascular Diseases/metabolism , Tetrazoles/metabolism , Vasodilator Agents/metabolism , Aged , Apolipoproteins/blood , Arteriosclerosis/drug therapy , Arteriosclerosis/metabolism , Blood Glucose/metabolism , Cilostazol , Fasting , Female , Glycated Hemoglobin/metabolism , Humans , Male , Middle Aged , Molecular Structure , Tetrazoles/chemistry , Tetrazoles/therapeutic use , Vasodilator Agents/chemistry , Vasodilator Agents/therapeutic use
6.
Int J Hematol ; 74(2): 178-85, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11594519

ABSTRACT

The clinicopathological features of 10 patients with primary mediastinal large B-cell lymphoma (PMLBCL) are described. The patients were aged 19 to 63 years, with a median age of 25.5 years. There were 5 men and 5 women. All patients presented with chest symptoms, and 6 presented with superior vena cava syndrome. Nine patients had bulky mediastinal tumors. The disease was confined within the thorax and contiguous lymph nodes, although multiple liver tumors were observed in 1 patient. Laboratory findings included high lactate dehydrogenase levels and elevated C-reactive protein levels. The soluble interleukin 2-receptor level was high in 6 patients tested. A comparative study of PMLBCL and nodular sclerosis-type Hodgkin's disease (NS-HD) with a mediastinal mass revealed substantial overlap in clinical features. Histopathological examination of biopsy specimens of PMLBCL revealed clusters of CD20+ large cells; however, CD30+ Hodgkin/Reed-Sternberg-like cells were occasionally seen, raising the potential to misdiagnose PMLBCL as NS-HD. The patients with PMLBCL were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), biweekly CHOP, or MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, and bleomycin) regimen, and 6 received consolidation radiotherapy to the involved field. With the exception of 1 patient who was primarily refractory to therapy, 9 patients (90%) achieved complete response and 7 (70%) remain in continuous remission with a mean follow-up of 24 months.


Subject(s)
Hodgkin Disease/diagnosis , Lymphoma, B-Cell/diagnosis , Lymphoma, Large B-Cell, Diffuse/diagnosis , Mediastinal Neoplasms/diagnosis , Adult , Antigens, CD20/analysis , Antigens, Neoplasm/analysis , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Diagnosis, Differential , Female , Hodgkin Disease/drug therapy , Hodgkin Disease/pathology , Humans , Ki-1 Antigen/analysis , Lymph Nodes/pathology , Lymphoma, B-Cell/drug therapy , Lymphoma, Large B-Cell, Diffuse/drug therapy , Male , Mediastinal Neoplasms/drug therapy , Middle Aged , Sclerosis , Treatment Outcome
7.
Circulation ; 104(11): 1268-73, 2001 Sep 11.
Article in English | MEDLINE | ID: mdl-11551878

ABSTRACT

BACKGROUND: The tachycardia circuit in the fast-slow form of atrioventricular nodal reentrant tachycardia (FS-AVNRT) has not been convincingly defined. METHODS AND RESULTS: To define the tachycardia circuit, single extrastimuli were delivered during FS-AVNRT to 9 intra-atrial sites in 12 patients: the His bundle (HB) site; the superior portion of the HB site (S-HB); 3 arbitrarily divided sites on the AV junction extending from the HB site to the coronary sinus ostium (CSOS) (sites S, M, and I); the superior, posterior, and posteroinferior portions of the CSOS (S-CSOS, P-CSOS, and PI-CSOS, respectively); and the CSOS. The inferior portion of coronary sinus ostium (I-CSOS), at which the earliest retrograde activation was observed, was excluded. At each site, the longest coupling interval of the single extrastimulus that reset the tachycardia and the subsequent return cycle was measured. The mean tachycardia cycle length was 370+/-55 ms. The longest coupling intervals at sites S-HB, HB, S, M, I, CSOS, S-CSOS, P-CSOS, and PI-CSOS were 328+/-53, 360+/-55, 358+/-55, 358+/-54, 360+/-55, 338+/-56, 323+/-54, 331+/-56, and 321+/-58 ms, respectively, and the subsequent return cycles were 408+/-58, 371+/-55, 370+/-55, 372+/-56, 370+/-55, 396+/-56, 411+/-60, 405+/-58, and 412+/-59 ms, respectively. The longest coupling intervals at sites HB, S, M, and I were longer than those at S-HB, CSOS, S-CSOS, P-CSOS, and PI-CSOS (P<0.0001). The return cycles at sites HB, S, M, and I did not differ from the tachycardia cycle length, whereas those at CSOS, S-CSOS, P-CSOS, and PI-CSOS were longer than the tachycardia cycle length (P<0.0001). CONCLUSIONS: The perinodal atrium extending from the HB site to the I-CSOS is an integral limb of the reentry circuit in FS-AVNRT.


Subject(s)
Atrioventricular Node/physiopathology , Tachycardia, Atrioventricular Nodal Reentry/physiopathology , Adolescent , Adult , Aged , Aged, 80 and over , Bundle of His/physiopathology , Catheter Ablation , Electrocardiography , Female , Heart Atria/physiopathology , Heart Conduction System/physiopathology , Humans , Male , Middle Aged , Tachycardia, Atrioventricular Nodal Reentry/surgery
8.
Acta Oncol ; 40(4): 485-90, 2001.
Article in English | MEDLINE | ID: mdl-11504308

ABSTRACT

This study investigates the relationship between the clinical features of lymphoma in the ocular adnexal region and the revised European and American lymphoma (REAL) classification. Specimens from 41 patients with ocular adnexal lymphoproliferative disease were reassessed pathologically using the REAL classification. Thirty-two patients with primary non-Hodgkin's lymphomas (NHL) were included in the study, almost all of them having been treated with radiotherapy with or without chemotherapy. Seven of the 32 patients with NHL showed distant recurrence after treatment: 3 out of 26 with extranodal marginal zone B-cell lymphoma, and 4 with other types of NHL. Although the three patients with recurrent marginal zone B-cell lymphomas all survived, other patients with recurrent lymphomas died of disease. The REAL classification provides a good indication of tumor control probability and survival of patients with ocular adnexal NHL. Radiation therapy is an effective treatment modality for extranodal marginal zone B-cell lymphoma of the ocular adnexa.


Subject(s)
Conjunctival Neoplasms/epidemiology , Eyelid Neoplasms/epidemiology , Lacrimal Apparatus Diseases/epidemiology , Lymphoma, Non-Hodgkin/epidemiology , Orbital Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Adjuvant , Cohort Studies , Combined Modality Therapy , Conjunctival Neoplasms/drug therapy , Conjunctival Neoplasms/pathology , Conjunctival Neoplasms/radiotherapy , Cyclophosphamide/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Eyelid Neoplasms/drug therapy , Eyelid Neoplasms/pathology , Eyelid Neoplasms/radiotherapy , Female , Humans , Immunoenzyme Techniques , Immunophenotyping , Japan/epidemiology , Lacrimal Apparatus Diseases/drug therapy , Lacrimal Apparatus Diseases/pathology , Lacrimal Apparatus Diseases/radiotherapy , Life Tables , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/pathology , Lymphoma, Non-Hodgkin/radiotherapy , Lymphoproliferative Disorders/epidemiology , Lymphoproliferative Disorders/pathology , Male , Middle Aged , Neoplasm Staging , Orbital Neoplasms/drug therapy , Orbital Neoplasms/pathology , Orbital Neoplasms/radiotherapy , Prednisone/administration & dosage , Radiotherapy, High-Energy/adverse effects , Retrospective Studies , Survival Analysis , Treatment Outcome , Vincristine/administration & dosage
9.
Nephrol Dial Transplant ; 16(9): 1776-82, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11522858

ABSTRACT

BACKGROUND: Glomerular crescents play an important role in progressive glomerular injury. The lesions consist of epithelial cells, macrophages, and deposits of fibrin and extracellular matrix. Transforming growth factor beta (TGF-beta) contributes to the modulation of cell growth and extracellular matrix synthesis. Thrombin is involved in fibrin formation in crescents. The purpose of this study was to examine whether glomerular epithelial cells (GEC) could produce TGF-beta, and if so, to clarify the role of TGF-beta in GEC proliferation. We also investigated whether thrombin could modulate the production of TGF-beta and extracellular matrix by GEC. METHODS: Bioassay using the TGF-beta-dependent mink pulmonary epithelial cell line (CCL-64), immunoblot analysis, and reverse transcriptase polymerase chain reaction (RT-PCR) were used to demonstrate TGF-beta production by rat GEC. TGF-beta gene expression was examined by RT-PCR in GEC incubated with thrombin, and type IV collagen and fibronectin were quantified by enzyme immunoassay in culture supernatants of GEC incubated with thrombin or TGF-beta. RESULTS: TGF-beta activity was demonstrated in GEC supernatants by bioassay. Immunoblot analysis of concentrated culture supernatants using anti-TGF-beta antibody revealed a 12.5-kDa protein, which was compatible with TGF-beta. Concentrated GEC supernatants inhibited GEC proliferation as well as porcine TGF-beta. RT-PCR demonstrated TGF-beta gene expression in GEC. Thrombin (0.5-5.0 U/ml) enhanced TGF-beta mRNA expression in a dose-dependent manner. Thrombin (5.0 U/ml) and porcine TGF-beta (5.0 ng/ml) stimulated the production of type IV collagen and fibronectin by GEC. CONCLUSIONS: Rat GEC produce TGF-beta in vitro. Thrombin may participate in the progression of glomerulosclerosis in crescentic glomerulonephritis through the stimulation of TGF-beta production by GEC.


Subject(s)
Gene Expression , Kidney Glomerulus/physiology , Thrombin/pharmacology , Transforming Growth Factor beta/biosynthesis , Transforming Growth Factor beta/genetics , Animals , Cell Division/drug effects , Cells, Cultured , Collagen Type IV/biosynthesis , Epithelial Cells/cytology , Epithelial Cells/physiology , Fibronectins/biosynthesis , Gene Expression/drug effects , Kidney Glomerulus/cytology , Rats , Swine
10.
Nephrol Dial Transplant ; 16(6): 1149-55, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11390713

ABSTRACT

BACKGROUND: The proliferation of glomerular epithelial cells (GEC) is usually observed in crescentic glomerulonephritis. However, the regulation of GEC proliferation is not fully understood. Although it is known that interleukin-1beta (IL-1beta) has a mitogenic effect on mesangial cells and is produced by mesangial cells, the effect of this cytokine on GEC proliferation is not known. We investigated whether cultured rat GEC could produce IL-1beta, and the role of IL-1beta on GEC proliferation. METHODS: Cultured rat GEC from 24th to 36th passage were used. GEC proliferation was evaluated with a colorimetric assay using the tetrazolium salt. GEC were incubated in K1 medium for 72 h and IL-1beta in the culture supernatants was measured by specific enzyme-linked immunosorbent assay (ELISA). IL-1beta in GEC supernatants was examined by immunoblot analysis. IL-1beta mRNA expression in GEC was examined by reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: IL-1beta showed a mitogenic effect on GEC, while interferon-gamma (IFN-gamma) and heparin inhibited GEC proliferation. Moreover, GEC proliferation cultured with K1 medium was partially inhibited by anti-IL-1beta neutralizing antibody. Amounts of IL-1beta in the culture supernatants increased over time (24-72 h). K1 medium increased IL-1beta production by GEC, while IFN-gamma or heparin did not change IL-1beta production. Immunoblot analysis revealed 17 kD protein of IL-1beta in the concentrated GEC supernatants. RT-PCR also demonstrated mRNA expression of IL-1beta in GEC. CONCLUSIONS: Our data indicate that IL-1beta is an autocrine growth factor for GEC and may have an important role in the regulation of GEC proliferation.


Subject(s)
Interleukin-1/physiology , Kidney Glomerulus/cytology , Urothelium/cytology , 3T3 Cells , Animals , Cell Division/drug effects , Cell Survival/drug effects , Cells, Cultured , Culture Media, Conditioned , Culture Media, Serum-Free , Heparin/pharmacology , Interferon-gamma/pharmacology , Interleukin-1/genetics , Interleukin-1/pharmacology , Kidney Glomerulus/physiology , Kinetics , Male , Mice , Rats , Rats, Sprague-Dawley , Recombinant Proteins , Transcription, Genetic , Urothelium/drug effects , Urothelium/physiology
11.
Breast Cancer ; 8(2): 153-7, 2001.
Article in English | MEDLINE | ID: mdl-11342989

ABSTRACT

BACKGROUND: The purpose of this study was to evaluate the results of breast-conserving therapy (BCT), defined as the combination of breast-conserving surgery with axillary dissection and definitive radiation therapy for ductal carcinoma in situ (DCIS). METHODS: Between November 1987 and March 1998, 33 patients with DCIS undergoing BCT at our hospital were examined. The mean age was 48. All patients underwent quadrantectomy or wide excision as well as axillary dissection. Radiation therapy consisted of 50 Gy to the ipsilateral whole breast. Boost irradiation of 10 Gy was given to 15 patients with close or positive margins. Nearly all patients received adjuvant chemotherapy with 5-fluorouracil or its derivatives and adjuvant endocrine therapy with tamoxifen for 2 years. RESULTS: The minimum and median follow-up periods were 32 and 80 months, respectively. All patients but one were followed. Only one patient had a non-invasive local recurrence, 23 months after her operation. This patient was salvaged with simple mastectomy. Her prognostic index score was 8. The five-year local control rate was 97%. No serious acute or late complications were noted. CONCLUSION: The results of this retrospective study substantiate favorable data and appear to confirm the efficacy and reasonable local recurrence rate of BCT for the treatment of DCIS.


Subject(s)
Breast Neoplasms/surgery , Carcinoma, Intraductal, Noninfiltrating/surgery , Mastectomy, Segmental , Adult , Aged , Breast Neoplasms/epidemiology , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Carcinoma, Intraductal, Noninfiltrating/epidemiology , Carcinoma, Intraductal, Noninfiltrating/pathology , Carcinoma, Intraductal, Noninfiltrating/radiotherapy , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Japan/epidemiology , Mastectomy, Segmental/methods , Middle Aged , Prognosis
12.
AJR Am J Roentgenol ; 176(6): 1499-507, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11373220

ABSTRACT

OBJECTIVE: The objective of this study was to determine the MR imaging features of intrahepatic cholangiocarcinoma. MATERIALS AND METHODS: MR images of 50 patients with pathologically proven intrahepatic cholangiocarcinoma were reviewed retrospectively. T1- and T2-weighted spin-echo images were obtained in all patients. Contrast-enhanced T1-weighted imaging was performed in 25 patients. Signal intensity and enhancement pattern of the tumors were correlated with pathology findings. The frequency of central hypointense regions on T2-weighted images and the intrahepatic bile duct dilatation of several other hepatic tumor types were investigated. Results were compared with imaging results of cholangiocarcinoma. RESULTS: On T2-weighted images, central hypo- and hyperintense regions were detected in tumors in 27 and 17 patients, respectively. Contrast-enhanced T1-weighted imaging revealed central hypointense areas exhibiting homogeneous, heterogeneous, and no enhancement in six, three, and five, respectively, of 14 patients. Regions of fibrosis displayed enhancement, whereas those of coagulative necrosis showed no enhancement. The signal intensity difference on T2-weighted images between the center and the edge of the tumor correlated well with the fibrotic ratio difference between those two areas corresponding to the MR image (Spearman's rank correlation test, r = 0.72, 95% confidence interval = 0.48-0.86). T2-weighted images revealed central hypointense regions in 16 of 34 instances of hepatic colorectal metastases. However, hypointensity was observed in only 26 of 234 other hepatic tumors. Intrahepatic bile duct dilatation was evident in 27 of 50 cases of cholangiocarcinoma but occurred in only a single case of 34 instances of hepatic colorectal metastases. CONCLUSION: The combination of the signal intensity on T2-weighted images and the enhancement pattern on contrast-enhanced T1-weighted images showed good correlation with the pathologic findings of cholangiocarcinoma. The occurrence of a central hypointense area on T2-weighted images is not pathognomonic; however, this finding, which reflects severe fibrosis, appears to be a characteristic marker of intrahepatic cholangiocarcinoma. The presence of intrahepatic bile duct dilatation may indicate cholangiocarcinoma, although it is difficult to differentiate cholangiocarcinoma from hepatic colorectal metastasis.


Subject(s)
Bile Duct Neoplasms/pathology , Bile Ducts, Intrahepatic/pathology , Cholangiocarcinoma/pathology , Magnetic Resonance Imaging , Contrast Media , Female , Gadolinium DTPA , Humans , Male , Middle Aged , Retrospective Studies
14.
Nephron ; 86(4): 467-72, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11124596

ABSTRACT

BACKGROUND: Mesangial cell proliferation and matrix accumulation are hallmarks of various progressive glomerular diseases. We examined whether C-type natriuretic peptide (CNP) that is known to regulate the proliferation of vascular smooth muscle cells could modulate these pathological processes using human glomerular mesangial cells (GMCs) in culture. METHODS: Proliferation of GMCs cultured with different concentrations of CNP-22 for 48 h was determined by a colorimetric assay using a tetrazolium salt. Monocyte chemoattractant protein-1 (MCP-1) and type IV collagen secretion into the culture media by GMCs in the presence or absence of CNP-22 were evaluated by ELISA. Expression of mRNA for natriuretic peptide receptor B (NPR-B), a specific receptor for CNP, was examined by reverse transcription polymerase chain reaction (RT-PCR). RESULTS: CNP-22 (1-10 microM) inhibited serum-induced GMC growth in a dose-dependent manner. The amount of MCP-1 in the culture supernatant was increased approximately 2.4-fold by 5 microg/ml of lipopolysaccharide. This increase was inhibited by CNP-22 at 0.1-1 microM in a dose-dependent fashion. CNP-22 (10 microM) inhibited GMC type IV collagen secretion stimulated by 20 ng/ml of platelet-derived growth factor. Expression of NPR-B mRNA was confirmed in GMCs by RT-PCR. CONCLUSIONS: CNP suppresses GMC proliferation and MCP-1 and type IV collagen secretion by GMCs. It may have a therapeutic potential against human proliferative glomerular diseases, especially those with the involvement of monocytes.


Subject(s)
Chemokine CCL2/metabolism , Glomerular Mesangium/cytology , Glomerular Mesangium/metabolism , Natriuretic Peptide, C-Type/pharmacology , Cell Division/drug effects , Cells, Cultured , Chemokine CCL2/biosynthesis , Chemokine CCL2/genetics , Collagen/metabolism , Culture Media/analysis , Depression, Chemical , Glomerular Mesangium/drug effects , Humans , RNA, Messenger/biosynthesis , Receptors, Atrial Natriuretic Factor/genetics , Receptors, Atrial Natriuretic Factor/metabolism , Reverse Transcriptase Polymerase Chain Reaction
15.
Pathol Int ; 50(10): 839-46, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11107057

ABSTRACT

A case of a 74-year-old man with leiomyosarcoma of the pulmonary vein is reported. The patient felt transient chest oppression while playing golf 1 week before he visited a clinic with a common cold. He underwent an ultrasonographic examination of the heart, which showed a mass lesion in the left atrium. The preoperative clinical diagnosis was myxoma of the left atrium. Cardiac surgery revealed the mass to be a leiomyosarcoma, probably extending from the left inferior pulmonary vein. The patient underwent a left lower lobectomy of the lung, and the tumor was confirmed to have originated from the wall of the left inferior pulmonary vein. Although the patient had a metastatic lesion in the right axillary lymph node 11 months later, which was excised, he remained free of disease 14 months after the initial operation. Histologically, the tumors were composed of pleomorphic cells with bizarre nuclei and spindle cells with blunt-ended nuclei with 1-4 mitotic figures in 10 high power fields. Immunohistologically, the tumor cells were positive for alpha-smooth muscle actin and desmin. We reviewed 17 cases of leiomyosarcoma of the pulmonary vein (six males and 11 females with a mean age of 50 years in each group). The present case was the oldest in age and to our knowledge was the first reported case with metastasis in a distant lymph node.


Subject(s)
Leiomyosarcoma/secondary , Lung/blood supply , Pulmonary Veins/pathology , Soft Tissue Neoplasms/pathology , Vascular Neoplasms/pathology , Aged , Axilla , Biomarkers, Tumor/analysis , Heart Atria/pathology , Heart Atria/surgery , Humans , Immunohistochemistry , Leiomyosarcoma/chemistry , Leiomyosarcoma/surgery , Lung/pathology , Lung/surgery , Lymph Nodes/pathology , Lymphatic Metastasis/pathology , Male , Neoplasm Proteins/analysis , Pulmonary Veins/chemistry , Pulmonary Veins/surgery , Soft Tissue Neoplasms/chemistry , Soft Tissue Neoplasms/surgery , Vascular Neoplasms/chemistry , Vascular Neoplasms/surgery
16.
Blood ; 96(9): 2993-3000, 2000 Nov 01.
Article in English | MEDLINE | ID: mdl-11049976

ABSTRACT

Anaplastic large cell lymphoma (ALCL) is a distinct entity of non-Hodgkin lymphoma, characterized by a proliferation of pleomorphic large lymphoid cells that express CD30. Recent studies have found that a subset of ALCL aberrantly expresses a chimeric anaplastic lymphoma kinase (ALK) protein as a result of t(2;5)(p23;q35) or variant translocations. ALK-positive ALCLs feature good prognosis, but some of them lead to poor outcomes. Since CD56 is expressed in some ALCLs, its clinical significance was examined in a series of T/null cell type ALCLs. Of 143 patients, 83 (58%) showed ALK-positive staining, and of 140 patients, 25 (18%) expressed CD56. The ALK-positive subgroup was characterized by a younger age of onset (P <.0001), lower serum lactate dehydrogenase level (P =.01), better performance status (P =.03), less frequent extranodal involvement (P =.01), lower international prognostic index (IPI) categories (P =.002), and superior survival (P =.0009) in comparison with the ALK-negative group, suggesting that ALK is a specific marker defining a distinct subtype. CD56(+) cases showed a significantly poor prognosis overall (P =.002) as well as in both ALK-positive and ALK-negative subgroups (P =.02 and P =.04, respectively). Multivariate analysis confirmed that CD56 is independent of other prognostic factors, including IPI. Although CD56(+) cases showed a higher incidence of bone involvement, no other differences in clinicopathologic parameters were found between the CD56(+) and CD56(-) groups. These findings suggest that CD56 is not a marker to identify a distinct subtype of ALCL, but a strong clinical prognostic factor. Effective therapeutic approaches should be explored for high-risk ALCL patients, who can be identified by means of a prognostic model, including CD56.


Subject(s)
Biomarkers, Tumor/analysis , CD56 Antigen/analysis , Lymphoma, Large B-Cell, Diffuse/immunology , Lymphoma, Large B-Cell, Diffuse/pathology , Protein-Tyrosine Kinases/analysis , Adolescent , Adult , Age of Onset , Aged , Aged, 80 and over , Anaplastic Lymphoma Kinase , Antigens, CD/analysis , Child , Child, Preschool , Female , Humans , Immunophenotyping , Infant , Lymphoma, Large B-Cell, Diffuse/classification , Lymphoma, Large B-Cell, Diffuse/mortality , Male , Middle Aged , Predictive Value of Tests , Prognosis , Receptor Protein-Tyrosine Kinases , Survival Rate , T-Lymphocytes/immunology
17.
Blood ; 96(8): 2907-9, 2000 Oct 15.
Article in English | MEDLINE | ID: mdl-11023530

ABSTRACT

Chromosomal translocation involving the BCL6 gene affects not only immunoglobulin (Ig) genes but also a number of non-Ig genes as partners. The molecular anatomy of the BCL6 gene rearrangements in 39 cases with diffuse large B-cell lymphoma (DLBCL) by long-distance polymerase chain reaction-based assays was determined. The results showed that Ig genes were affected in 21 cases; non-Ig genes, 15 cases; a deletion of more than a 1-kb segment, 2 cases; and a point mutation, 1 case. Comparative studies between the 21 cases with Ig gene partners and the 17 cases with non-Ig gene partners, including 2 cases with the deletion, showed that the overall survival of the latter group of patients was significantly inferior to that of the former (P = .0440), and the estimated 2-year overall survival rates were 58.3% vs 17.6% (P = .005). Non-Ig/BCL6 fusion is a poor prognostic indicator of DLBCL, and DLBCL with BCL6 translocation could be subclassified according to the individual partner locus and/or gene. (Blood. 2000;96:2907-2909)


Subject(s)
DNA, Neoplasm/genetics , DNA-Binding Proteins/genetics , Genes, Immunoglobulin , Lymphoma, Large B-Cell, Diffuse/genetics , Proto-Oncogene Proteins/genetics , Transcription Factors/genetics , Translocation, Genetic , Adult , Aged , Chromosomes, Human, Pair 1/genetics , Chromosomes, Human, Pair 14/genetics , Chromosomes, Human, Pair 16/genetics , Chromosomes, Human, Pair 3/genetics , Chromosomes, Human, Pair 7/genetics , DNA Mutational Analysis , Female , Humans , Life Tables , Lymphoma, Large B-Cell, Diffuse/mortality , Male , Middle Aged , Point Mutation , Polymerase Chain Reaction , Prognosis , Proto-Oncogene Proteins c-bcl-6 , Sequence Deletion , Survival Analysis , Survival Rate
18.
J Comput Assist Tomogr ; 24(4): 605-9, 2000.
Article in English | MEDLINE | ID: mdl-10966195

ABSTRACT

We report the radiologic and pathologic features of yolk sac tumor (endodermal sinus tumor) of the ovary in four patients. Yolk sac tumors were shown as well-enhancing solid tumors on both CT and MR studies and were associated with prominent signal voids on MRI. A hypervascular nature was confirmed on microscopic studies. Areas of hemorrhage were another common characteristic. These imaging findings seem to have an important implication for the diagnosis of this tumor.


Subject(s)
Endodermal Sinus Tumor/diagnosis , Magnetic Resonance Imaging , Ovarian Neoplasms/diagnosis , Tomography, X-Ray Computed , Adolescent , Adult , Child , Endodermal Sinus Tumor/diagnostic imaging , Endodermal Sinus Tumor/pathology , Female , Humans , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/pathology
19.
Int J Radiat Oncol Biol Phys ; 48(1): 153-60, 2000 Aug 01.
Article in English | MEDLINE | ID: mdl-10924985

ABSTRACT

PURPOSE: We re-evaluated histopathological specimens of head and neck early-stage extranodal non-Hodgkin's lymphoma (NHL) using the revised European and American lymphoma (REAL) classification, and also investigated the relationship between the clinical characteristics and histopathological classification in an attempt to evaluate the usefulness of this new classification system in selecting treatment modalities. MATERIALS AND METHODS: Between 1979 and 1995, 117 patients with histologically confirmed stages I and II NHL of head-and-neck extranodal regions were treated. Of these patients, 110 specimens were available for re-evaluation. Sixty-four patients had Stage I, and 46 had Stage II diseases. All but 3 had received radiation therapy, and 59 patients were also treated with intensive combination chemotherapy. RESULTS: There were 32 extranodal marginal-zone B-cell lymphomas, 57 diffuse large B-cell lymphomas, 11 peripheral T/NK-cell lymphomas, and 10 others. The 5- and 10-year cause-specific survival rates for all patients were 72% and 62%, respectively. Patients with extranodal marginal-zone B-cell lymphoma or other low-grade B-cell lymphomas demonstrated higher survival rates than patients with other lymphomas. Patients with peripheral T/NK lymphomas showed the lowest survival rate. CONCLUSION: The REAL classification accurately indicated the prognosis of patients with NHL. These results suggest that appropriate treatment modalities can be selected using this classification.


Subject(s)
Head and Neck Neoplasms/classification , Lymphoma, Non-Hodgkin/classification , Adolescent , Adult , Aged , Aged, 80 and over , Combined Modality Therapy , Female , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/therapy , Humans , Lymphoma, B-Cell/classification , Lymphoma, B-Cell/pathology , Lymphoma, B-Cell/therapy , Lymphoma, Large B-Cell, Diffuse/classification , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Large B-Cell, Diffuse/therapy , Lymphoma, Non-Hodgkin/pathology , Lymphoma, Non-Hodgkin/therapy , Lymphoma, T-Cell/classification , Lymphoma, T-Cell/pathology , Lymphoma, T-Cell/therapy , Male , Middle Aged , Neoplasm Staging , Radiotherapy Dosage , Survival Rate
20.
Ann Nucl Med ; 14(3): 187-92, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10921483

ABSTRACT

PURPOSE: Resting 123I-BMIPP scintigraphy can detect coronary artery disease based on persistent abnormality of myocardial fatty acid metabolism after transient ischemia. The present study aimed to determine the value of resting 123I-BMIPP scintigraphy in diagnosing coronary artery disease and predicting the therapeutic outcome in patients with chest pain symptom. METHOD: Five hospitals participated in this study, and scintigraphic and angiographic studies were performed in 104 patients without myocardial infarction. Twenty of them had non-coronary artery disease (chest pain syndrome), 26 had stable effort angina, 35 had unstable angina with organic coronary lesions, and 23 had vasospastic angina without significant organic stenosis. RESULTS: Overall sensitivity for diagnosing angina pectoris (stable, unstable and vasospastic) was 45%, and overall specificity for excluding non-coronary artery disease was 80%. The incidence of positive 123I-BMIPP was 54% among patients with organic coronary stenosis (50% in stable angina and 61% in unstable angina with organic stenosis), but it was low (22%) in vasospastic angina without organic stenosis. Patients with advanced coronary stenosis and multi-vessel disease were found to have a higher incidence of positive 123I-BMIPP. A positive 123I-BMIPP result was correlated with a higher rate of subsequent intervention therapy (catheter intervention or CABG) than a negative result (48% versus 27%, p = 0.03 at one month; and 63% versus 35%, p = 0.008 at one year). CONCLUSION: Resting 123I-BMIPP scintigraphy was valuable in detecting advanced coronary lesions in angina patients associated with a high incidence of subsequent intervention therapy.


Subject(s)
Chest Pain , Coronary Disease/diagnostic imaging , Fatty Acids , Iodine Radioisotopes , Iodobenzenes , Aged , Analysis of Variance , Angioplasty, Balloon, Coronary , Chi-Square Distribution , Coronary Angiography , Coronary Artery Bypass , Coronary Disease/diagnosis , Coronary Disease/therapy , Echocardiography , Female , Follow-Up Studies , Humans , Male , Reproducibility of Results , Tomography, Emission-Computed, Single-Photon , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...